Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2017
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
27 March 2017 15:00 BST
TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES
AstraZeneca
PLC (the Company) announces that, on 24 March 2017, certain Persons
Discharging Managerial Responsibilities of the Company (PDMRs) were
each granted awards of the Company's ordinary shares of $0.25 each
(Ordinary Shares) or of American Depositary Shares (ADSs) under the
terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the
AstraZeneca Performance Share Plan (AZPSP), as detailed in the
table below. Two ADSs are equivalent to one Ordinary
Share.
|
PDMR
|
Ordinary Shares awarded under the AZDBP
|
ADSs awarded under the AZDBP
|
Ordinary Shares awarded under the AZPSP
|
ADSs awarded under the AZPSP
|
Award price per Ordinary Share / per ADS
|
|
Pascal Soriot
|
7,968
|
|
125,009
|
|
£48.80
|
|
Marc Dunoyer
|
4,262
|
|
59,439
|
|
£48.80
|
|
Sean Bohen
|
|
3,452
|
|
97,507
|
$30.88
|
|
Mark Mallon
|
|
2,503
|
|
82,190
|
$30.88
|
The
AZDBP award represents the portion of each PDMR's annual bonus for
2016 that they are required to defer into shares. The Ordinary
Shares and ADSs awarded under the AZDBP are subject to a three-year
holding period (24 March 2017 to 23 March 2020).
The
AZPSP award is subject to a combination of performance measures
focused on scientific, commercial and financial performance
assessed over a three-year performance period (1 January 2017 to 31
December 2019). The AZPSP award will vest on the third anniversary
of the date of grant, other than the awards granted to the
Executive Directors, Mr Soriot and Mr Dunoyer, which will be
subject to a further two-year holding period before
vesting.
Details
of the performance measures attached to the AZPSP award can be
found in the Directors' Remuneration Report within the AstraZeneca
Annual Report and Form 20-F Information 2016, which is available on
the Company's website at www.astrazeneca.com/annualreport2016.
The
Company also announces that, on 24 March 2017, Mr Bohen was granted
an award of 48,753 ADSs under the terms of the AstraZeneca
Restricted Share Plan (AZRSP) at an award price of $30.88 per ADS.
The ADSs awarded under the AZRSP are subject to continued
employment and will vest on the third anniversary of the date of
grant.
About AstraZeneca
AstraZeneca
is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three main
therapy areas - Oncology, Cardiovascular & Metabolic Diseases
and Respiratory. The Company also is selectively active in the
areas of Autoimmunity, Neuroscience and Infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
|
Media Enquiries
|
|
|
|
Esra
Erkal-Paler
|
UK/Global
|
+44 203 749 5638
|
|
Vanessa
Rhodes
|
UK/Global
|
+44 203 749 5736
|
|
Karen
Birmingham
|
UK/Global
|
+44 203 749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203 749 5821
|
|
Jacob
Lund
|
Sweden
|
+46 8 553 260 20
|
|
Michele
Meixell
|
US
|
+1 302 885 2677
|
|
Investor Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203 749 5712
|
|
Craig
Marks
|
Finance, Fixed Income, M&A
|
+44 7881 615 764
|
|
Henry
Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Mitchell
Chan
|
Oncology
|
+1 240 477 3771
|
|
Lindsey
Trickett
|
Cardiovascular & Metabolic Diseases
|
+1 240 543 7970
|
|
Nick
Stone
|
Respiratory
|
+44 203 749 5716
|
|
Christer
Gruvris
|
Autoimmunity, Neuroscience & Infection
|
+44 203 749 5711
|
|
US
toll free
|
|
+1 866 381 7277
|
Adrian Kemp
Company Secretary, AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
|
Date:
27 March 2017
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|